ADHD, dopamine, and the risks people underplay

Not a tank that ran dry#

People say ADHD means low dopamine. It is a useful shorthand, and it is also how a lot of people end up wrong.

You do not walk around with an empty jar of a neurotransmitter. What the better studies show is messier and more specific: parts of the dopamine reward pathway look disrupted, especially the bits that handle motivation, reinforcement, and the difference between a small reward now and a better one later.

Nora Volkow's PET work is the paper people should actually read before they tweet about chemistry. In adults with ADHD, measures of dopamine D2/D3 receptors and dopamine transporters were lower in the nucleus accumbens and midbrain, the core of the mesoaccumbens reward circuit. Those readings tracked with inattention. A follow-up analysis tied the same pathway to motivation and achievement scores. The clinical translation is blunt: ordinary tasks do not land as rewarding enough, so attention and effort do not stick.

That is not the same as "ADHD brains have no dopamine". A 2024 Frontiers review went through decades of human and animal evidence and concluded that dopamine is involved, but the simple hypo-dopaminergic story does not hold as a clean global deficit. Signalling, region, development, and other neurotransmitter systems all sit in the mix. Popular content collapses that into a slogan. The slogan sells supplements. It does not explain the condition.

None of this is medical advice. I am not a clinician. I am someone who has watched the neurodivergence conversation flatten biology into memes, and then watched people pay for that flattening with their health.

What low reward signalling feels like from the outside#

If ordinary rewards under-fire, the nervous system goes looking for intensity.

That is the behavioural half of the dopamine story. Delayed gratification gets harder. Boredom feels hostile. Novel, fast, high-salience inputs win: scrolling, betting apps, nicotine, caffeine stacked on caffeine, porn, gaming, argument, driving too fast, starting five projects and finishing none. From outside it looks like indiscipline. From inside it often feels like trying to get a flat system to register that something matters.

The NHS description of adult ADHD is plainer than most forums: inattention, impulsivity, restlessness, and real impairment across life. The reward-pathway work helps explain why "just try harder" fails as a plan. Effort is downstream of a signal that something is worth the effort.

There is a trap here. Once you learn the word dopamine, every craving gets a neurological alibi. Some of those behaviours are ADHD-shaped. Some are depression, trauma, sleep debt, alcohol, or a phone designed by a team paid to capture attention. Chemistry is part of the picture. It is not a free pass, and it is not a diagnosis.

The risks people underplay#

This is the part soft content skips.

ADHD is associated with higher mortality. In a Danish nationwide cohort, people with ADHD had roughly double the mortality rate of people without it. Accidents were the main driver. A 2025 meta-analysis covering more than 15 million people found elevated all-cause mortality, suicide mortality, injury mortality, and natural-cause mortality. Medication use was associated with lower all-cause mortality in that synthesis. Observational data cannot prove causation the way a perfect trial would. It is still a pattern you should not shrug off.

In the UK, O'Nions and colleagues estimated that adults with diagnosed ADHD lost about 6.8 years of life expectancy for men and 8.6 for women compared with matched controls. The authors themselves say this is likely driven by modifiable risks and unmet support, not by ADHD as a mystical death sentence, and that diagnosed adults may over-represent people with heavier comorbidity. The caution matters. So does the headline: shorter lives, in a health system that still treats adult ADHD as optional.

Substance use is the other obvious risk. ADHD raises the odds of later drug use disorder substantially. In a Swedish population study, ADHD before 15 carried more than a threefold hazard of later drug use disorder after adjustment. Reviews put adult substance use disorder rates in ADHD at roughly two to three times the background rate, and some clinical samples higher still. Impulsivity, sensation seeking, and a reward system that under-responds to ordinary reinforcement are not a mystery recipe for addiction. They are the recipe.

That does not mean prescribed stimulants create addicts as a rule. The same literature finds that treatment is not the engine of later substance abuse, and some registry data link stimulant treatment to lower substance abuse rates. The bigger danger is the untreated pattern: self-medicating with alcohol, cannabis, cocaine, nicotine, or whatever else briefly turns the volume up.

Then there are the quieter harms. Underemployment. Relationship rupture. Debt. Chronic shame. Anxiety and depression stacked on top. Sleep wrecked by late-night stimulation seeking. Driving risk. The compound interest of a hundred small impulsive decisions. Dopamine talk makes ADHD sound like a vibe. The outcomes are closer to a public health problem.

Medication is not the villain, and it is not free#

In the UK, NICE NG87 says adult ADHD medication should follow specialist assessment. First-line options for adults are usually methylphenidate or lisdexamfetamine, with atomoxetine when stimulants are not tolerated or not enough. These drugs increase catecholamine signalling. That is why they can help attention and why people with disrupted reward pathways often feel, for the first time, that a task can hold still.

They also have risks. Appetite drop, insomnia, anxiety, raised heart rate and blood pressure, mood changes. They are controlled medicines. Diversion and misuse are real, which is why NICE asks for substance-use risk assessment before starting. Cardiovascular history matters. Monitoring is not optional theatre: pulse, blood pressure, weight, and whether the drug is still doing the job.

So the honest frame is not "meds bad" or "meds magic". Untreated ADHD carries measurable risk. Treated ADHD still needs medical oversight. Buying research chemicals off a Telegram channel because a reel said your dopamine is low is not the same category of decision as shared care with a specialist. One of those has a pathway. The other has a story.

Environmental changes, sleep, exercise, therapy, and reducing the engineered dopamine buffet on your phone still matter. Medication without that work leaves a lot of risk on the table. Lifestyle advice without recognising the neurobiology is how people get told they are lazy for a decade.

If this sounds familiar#

Get assessed properly. In the UK that means an ADHD-capable specialist route, not a quiz result and a shopping cart. NHS pages on adult ADHD and NICE NG87 are the boring, useful starting points. Waiting lists are long. That is a systems failure, not proof you should diagnose yourself from TikTok.

While you wait, treat the modifiable risks as seriously as the label. Sleep. Alcohol. Nicotine. Driving when your attention is shot. Debt apps. Betting apps. Substances that promise a dopamine spike and collect interest later. If work or study is collapsing, ask for adjustments early instead of white-knuckling into a crisis.

And keep the chemistry honest. ADHD involves dopamine systems. It is not a petrol gauge. The risk is not that your brain has a slightly different reward curve. The risk is what that curve pushes people toward when nobody helps them steer: accidents, addiction, despair, and years of life quietly shaved off the end.

If you are struggling right now: Samaritans on 116 123, any time, free. NHS 111 and pick the mental health option. CALM on 0800 58 58 58. ADHD UK for condition-specific information and support routes. If you are in danger, 999.

References#

• Volkow et al., Evaluating dopamine reward pathway in ADHD (JAMA)
• Volkow et al., Motivation deficit in ADHD and the dopamine reward pathway (Molecular Psychiatry)
• The dopamine hypothesis for ADHD: evaluation of evidence (Frontiers in Psychiatry, 2024)
• NHS, ADHD symptoms
• NHS, ADHD in adults
• NICE NG87, Attention deficit hyperactivity disorder: diagnosis and management
• Dalsgaard et al., Mortality in ADHD: nationwide cohort (The Lancet)
• Mortality among people with ADHD: systematic review and meta-analysis (PMC)
• O'Nions et al., Life expectancy and years of life lost for adults with diagnosed ADHD in the UK (British Journal of Psychiatry)
• Sundquist et al., ADHD and risk for drug use disorder (PMC)
• Wilens, ADHD, substance use disorders and stimulant treatment (World Psychiatry)
• Samaritans
• CALM
• ADHD UK